New York State Common Retirement Fund Sells 341,274 Shares of RxSight, Inc. $RXST

New York State Common Retirement Fund reduced its position in RxSight, Inc. (NASDAQ:RXST) by 73.1% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 125,649 shares of the company’s stock after selling 341,274 shares during the period. New York State Common Retirement Fund’s holdings in RxSight were worth $1,130,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in RXST. Artisan Partners Limited Partnership lifted its holdings in shares of RxSight by 27.4% during the second quarter. Artisan Partners Limited Partnership now owns 2,252,544 shares of the company’s stock valued at $29,283,000 after purchasing an additional 485,021 shares in the last quarter. Kent Lake PR LLC purchased a new position in RxSight in the 2nd quarter worth about $3,900,000. BNP Paribas Financial Markets raised its position in RxSight by 123.7% in the 2nd quarter. BNP Paribas Financial Markets now owns 481,064 shares of the company’s stock worth $6,254,000 after buying an additional 265,989 shares during the last quarter. Federated Hermes Inc. bought a new position in RxSight during the 2nd quarter valued at about $3,397,000. Finally, Squarepoint Ops LLC boosted its holdings in shares of RxSight by 138.6% during the 2nd quarter. Squarepoint Ops LLC now owns 374,663 shares of the company’s stock valued at $4,871,000 after acquiring an additional 217,608 shares during the last quarter. 78.78% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

RXST has been the subject of a number of research reports. UBS Group reiterated a “neutral” rating on shares of RxSight in a research note on Monday, January 12th. Needham & Company LLC upped their price objective on RxSight from $11.00 to $12.00 and gave the company a “buy” rating in a research report on Thursday, November 6th. Wolfe Research raised RxSight to an “outperform” rating in a research report on Friday, January 30th. Stifel Nicolaus set a $10.00 price target on RxSight in a research note on Thursday, November 6th. Finally, JPMorgan Chase & Co. increased their price objective on shares of RxSight from $8.00 to $9.00 and gave the stock an “underweight” rating in a research note on Thursday, November 6th. Two analysts have rated the stock with a Buy rating, ten have issued a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Reduce” and a consensus price target of $9.78.

RxSight Price Performance

NASDAQ:RXST opened at $8.26 on Tuesday. The company has a market cap of $339.65 million, a price-to-earnings ratio of -9.39 and a beta of 1.14. The stock’s 50 day simple moving average is $10.51 and its two-hundred day simple moving average is $9.45. RxSight, Inc. has a 1 year low of $6.32 and a 1 year high of $33.08.

RxSight Profile

RxSight, Inc is a medical technology company focused on the development and commercialization of advanced intraocular lens (IOL) systems for patients undergoing cataract surgery and lens replacement procedures. The company’s flagship product, the Light Adjustable Lens (LAL), is designed to provide customized vision correction by allowing non‐invasive post‐operative adjustments. Using ultraviolet light, surgeons can fine‐tune the lens power after implantation to achieve optimal visual outcomes, reducing reliance on glasses or contact lenses and enhancing patient satisfaction.

Founded in 2011 and headquartered in Aliso Viejo, California, RxSight has pursued regulatory clearances and market access across multiple regions.